Laserscope and Exim sign marketing agreement:
This article was originally published in Clinica
Executive Summary
Lasercope, which manufactures medical lasers and surgical support products, granted Exim International marketing rights to sell its products in the People's Republic of China, Hong Kong and Vietnam. Exim specialises in trading with China, and estimates that the external investment in China's healthcare industry is about Yuan 85,000 million ($11 000 million), of which the medical device industry's investment is Yuan 2,000 million. Laserscope's products include KTP/532, CO(2), Nd:YAG, Er:YAG and ruby medical lasers.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.